Expert Practice
Expert Practice
Expert Practice

Expert Practice℠ in Pancreatic Cancer

Not a member of My prIME? Join now for instant access.

To apply for a travel grant, click on the Register Now button.

Meeting Overview

Join us at this multidisciplinary, interactive, case-based meeting to enrich your knowledge on molecular biology, imaging, and current standard of care in resectable, unresectable, and metastatic pancreatic cancer. In this 1.5-day meeting, experts in the field will provide their insight on how they would treat their patients and encourage you to ask questions and discuss the challenges you face in your clinical practice.

Date and Location

Friday and Saturday
29 – 30 September 2017

Ballroom
Hilton Budapest
Hess András tér 1-3
Budapest, Hungary

Date/Time

Date/Time

Friday and Saturday
29 – 30 September 2017

Location

Location

Budapest, Hungary

CME

CME

7.0 European CME Credits

Friday, 29 September

19.00 Buffet dinner
19.30 Welcome, introduction, and warm-up quiz
Philip Agop Philip, MD, PhD, FRCP, Eric Van Cutsem, MD, PhD, and prIME Oncology Medical Director
19.45 Setting the stage: Key milestones and challenges in the management of pancreatic cancer
Eric Van Cutsem, MD, PhD
20.10 Audience questions and faculty panel commentary
20.15 Hot topic debate: Should every patient with resectable pancreatic cancer receive upfront chemotherapy?
Yes: Christiane Bruns, MD, PhD
No: Gabriela Chiorean, MD
20.45 Audience questions and faculty panel commentary
21.00 Concluding remarks

Saturday, 30 September

07.30 Breakfast
08.30 Introduction and objectives of day 2
Philip Agop Philip, MD, PhD, FRCP, and Eric Van Cutsem, MD, PhD 
08.35 Keynote Lecture 1—Advances in molecular biology of pancreatic cancer: Understanding genetic complexity and molecular heterogeneity
Volker Ellenrieder, MD, PhD
09.00 Audience questions and faculty panel commentary
09.10 Imaging of pancreatic cancer: Current state of the art and future trends
Maria Antonietta Bali, MD, PhD
09.35 Audience questions and faculty panel commentary
09.45 Case #1—Resectable pancreatic ductal carcinoma
Christiane Bruns, MD, PhD (Part I), and Teresa Macarulla, MD, PhD (Parts II and III)
Part I: Advances in surgery
Part II: Current and emerging adjuvant therapies
Part III: Managing borderline resectable pancreatic cancer and follow-up strategies
10.40 Audience questions and faculty panel commentary
10.55 Coffee break
11.15 Case #2—Locally advanced unresectable pancreatic cancer: Evaluating treatment options
Stefano Cascinu, MD, PhD
11.45 Audience questions and faculty panel commentary
12.00 Selecting the primary endpoint for neoadjuvant and adjuvant clinical trials
Eric Van Cutsem, MD, PhD, and Faculty Panel
12.20 Keynote Lecture 2—Targeting the tumor microenvironment in pancreatic cancer
Gabriela Chiorean, MD
12.45 Audience questions and faculty panel commentary
12.55 Lunch
13.55 Case #3—Metastatic pancreatic ductal adenocarcinoma: Selecting an optimal first-line approach
Philip Agop Philip, MD, PhD, FRCP
14.25 Audience questions and faculty comments
14.40 Case #4—Progressive pancreatic cancer: Optimal sequencing of systemic therapy?
Gerald Prager, MD
15.10 Audience questions and faculty comments
15.25 Clinical opinion poll questions: Challenging the experts
Faculty Panel
15.40 Pancreatic cancer management in the coming year: What can we expect?
Philip Agop Philip, MD, PhD, FRCP
15.55 prIME Points™
Eric Van Cutsem, MD, PhD
16.00 Adjourn

    Co-Chairs

  • Philip Agop Philip, MD, PhD, FRCPWayne State University and Karmanos Cancer Institute
    Detroit, Michigan, United States
  • Eric Van Cutsem, MD, PhDUniversity Hospitals Leuven
    Leuven, Belgium
  • Faculty

  • Maria Antonietta Bali, MD, PhDInstitut Jules Bordet
    Free University of Brussels
    Brussels, Belgium
  • Christiane Bruns, MD, PhDUniversity of Cologne
    Cologne, Germany
  • Stefano Cascinu, MD, PhDUniversity of Modena and Reggio Emilia
    Modena, Italy
  • Gabriela Chiorean, MDUniversity of Washington
    Fred Hutchinson Cancer Research Center
    Seattle, Washington, United States
  • Volker Ellenrieder, MD, PhDUniversity Hospital Gӧttingen
    Gӧttingen, Germany
  • Teresa Macarulla, MD, PhDVall d’Hebron University Hospital
    Barcelona, Spain
  • Gerald Prager, MDMedical University of Vienna
    Vienna, Austria

This educational activity is designed for European surgical, radiation, and medical oncologists, gastroenterologists, and other healthcare providers involved in the management of patients with pancreatic cancer.

After successful completion of this educational activity, participants should be able to:

  • Describe the genomic complexity and molecular heterogeneity of pancreatic cancer
  • Explain advances in imaging modalities of pancreatic cancer and recognize imaging criteria defining resectability
  • Identify multimodality treatment strategies for localized resectable, borderline, and unresectable pancreatic cancer
  • Select the most appropriate therapeutic approach for metastatic pancreatic ductal adenocarcinoma based on patient and disease characteristics, both in the first-line setting and beyond
  • Assess supportive care measures to ameliorate disease symptoms and treatment-related adverse events throughout the course of pancreatic cancer management
  • Describe emerging treatment strategies in pancreatic cancer, including the role of immunotherapy

This educational activity is supported by grants from Celgene and Shire.

Continuing Education

Expert Practice℠ in Pancreatic Cancer held in Budapest, Hungary on 29/09/2017-30/09/2017 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 7.0 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/go/internationalcme .

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Good CME Practice

gCMEp-FINAL-logo-1

Provider

This activity is provided by prIME Oncology.

Sunshine Act and EFPIA Disclosure Code

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Disclosures

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.